A randomized, double-blind, placebo-controlled, parallelgroup, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab, in participants with non-cystic fibrosis bronchiectasis

Date Added
January 24th, 2025
PRO Number
Pro00142015
Researcher
Patrick Flume

List of Studies


Keywords
Bronchiectasis
Summary

This study is to evaluate an investigational study drug, itepekimab, for the treatment of bronchiectasis. The main purpose for this study is to assess the safety, efficacy, and tolerability of itepekimab in bronchiectasis in addition to the current background treatment you are receiving which may include bronchodilators, inhaled corticosteroids, mucolytics, and/or maintenance antibiotics. You will receive either the study drug or a placebo if you participate in this research. This study will include about 300 participants with bronchiectasis across approximately 20 countries worldwide.

Institution
MUSC
Recruitment Contact
Zerlinna Teague
8437920965
recruitment@musc.edu

Qualitative Interviews with Patients of the Brensocatib Post-Trial Access Program

Date Added
December 20th, 2024
PRO Number
Pro00141048
Researcher
Patrick Flume

List of Studies


Keywords
Bronchiectasis
Summary

This research seeks to gather important insights about patients' experiences of NCFBE-related exacerbations and brensocatib treatment by conducting semi-structured qualitative interviews in the USA. A total of up to 30 interviews of approximately one hour are planned. Patient must be at least 18 years old and currently participating in the brensocatib PTA program for at least 3 months.

Institution
MUSC
Recruitment Contact
Isabella Brookshire
8437920965
recruitment@musc.edu



-- OR --